Loading…

Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study

Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival fun...

Full description

Saved in:
Bibliographic Details
Published in:BMC research notes 2018-02, Vol.11 (1), p.90-90, Article 90
Main Authors: Rankgoane-Pono, Goabaone, Tshikuka, Jose Gaby, Magafu, Mgaywa Gilbert Mjungu Damas, Masupe, Tiny, Molefi, Mooketsi, Hamda, Shimeles Genna, Setlhare, Vincent, Tapera, Roy, Mbongwe, Bontle
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3
cites cdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3
container_end_page 90
container_issue 1
container_start_page 90
container_title BMC research notes
container_volume 11
creator Rankgoane-Pono, Goabaone
Tshikuka, Jose Gaby
Magafu, Mgaywa Gilbert Mjungu Damas
Masupe, Tiny
Molefi, Mooketsi
Hamda, Shimeles Genna
Setlhare, Vincent
Tapera, Roy
Mbongwe, Bontle
description Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen. The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X  = 8.98, p 
doi_str_mv 10.1186/s13104-018-3144-9
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b254dd1048f54ddc91a6e98eddb71fce</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546075038</galeid><doaj_id>oai_doaj_org_article_b254dd1048f54ddc91a6e98eddb71fce</doaj_id><sourcerecordid>A546075038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</originalsourceid><addsrcrecordid>eNptUstu1DAUjRCIlsIHsEGW2MAixY84iVlUKhXQkSp1A91aftxMPUrswXZa-iH8L56ZUjoIeWH7-pxz5XNPVb0m-JiQvv2QCCO4qTHpa0aaphZPqkPS8bbGHOOnj84H1YuUVhi3pO_J8-qACiYIZuKw-rXwxlnwBlAYkHVKQ4aEJhhHl-dURxhVBotMmELUzrrsyrOagl-itSoXn8s1Z_DWlVK-DWhSqxDR-eIKmdF5ZxJyHn0KOd0qrz4ihQit70BFFCHHkNZgsruB0uE6xIxSnu3dy-rZoMYEr-73o-r7l8_fzs7ri8uvi7PTi9pwLEStWSeoMcCoEtoI03DQzBDKtaCixZp2vcFGt0LwBtsOBCsGaAJsaBgRhXdULXa6NqiVXEc3qXgng3JyWwhxKVXMzowgNeWNtcXuftgcjCCqBdGDtbojw1brZKe1nvUE1hRnohr3RPdfvLuWy3AjeSfahvVF4N29QAw_ZkhZTi6ZMgjlIcxJElGmJjijTYG-_Qe6CnP0xSpJO0EYpViwv6ilKh9wfgilr9mIylPetLjjeNv2-D-osixMzgQPgyv1PcL7PULBZPiZl2pOSS4ur_axZIc1ZdIpwvDgB8Fyk2G5y7AsGZabDEtROG8eG_nA-BNa9hsPi-0n</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791322093</pqid></control><display><type>article</type><title>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</title><source>PMC</source><source>ProQuest - Publicly Available Content Database</source><creator>Rankgoane-Pono, Goabaone ; Tshikuka, Jose Gaby ; Magafu, Mgaywa Gilbert Mjungu Damas ; Masupe, Tiny ; Molefi, Mooketsi ; Hamda, Shimeles Genna ; Setlhare, Vincent ; Tapera, Roy ; Mbongwe, Bontle</creator><creatorcontrib>Rankgoane-Pono, Goabaone ; Tshikuka, Jose Gaby ; Magafu, Mgaywa Gilbert Mjungu Damas ; Masupe, Tiny ; Molefi, Mooketsi ; Hamda, Shimeles Genna ; Setlhare, Vincent ; Tapera, Roy ; Mbongwe, Bontle</creatorcontrib><description>Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen. The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X  = 8.98, p &lt; 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients' survival.</description><identifier>ISSN: 1756-0500</identifier><identifier>EISSN: 1756-0500</identifier><identifier>DOI: 10.1186/s13104-018-3144-9</identifier><identifier>PMID: 29391039</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Analysis ; Antiretroviral therapy ; Botswana ; Cohort analysis ; Combination antiretroviral therapy ; Comorbidity ; Complications and side effects ; Data collection ; Development and progression ; Diabetes ; Diabetes mellitus ; Diabetes-related comorbidities ; Distribution ; Drug therapy ; Health aspects ; Highly active antiretroviral therapy ; HIV ; HIV carriers ; Human immunodeficiency virus ; Incidence ; Medical records ; Patients ; PLHIV ; Research Note ; Sample size ; Survival ; Survival analysis ; Type 2 diabetes</subject><ispartof>BMC research notes, 2018-02, Vol.11 (1), p.90-90, Article 90</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</citedby><cites>FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796438/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2791322093?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29391039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rankgoane-Pono, Goabaone</creatorcontrib><creatorcontrib>Tshikuka, Jose Gaby</creatorcontrib><creatorcontrib>Magafu, Mgaywa Gilbert Mjungu Damas</creatorcontrib><creatorcontrib>Masupe, Tiny</creatorcontrib><creatorcontrib>Molefi, Mooketsi</creatorcontrib><creatorcontrib>Hamda, Shimeles Genna</creatorcontrib><creatorcontrib>Setlhare, Vincent</creatorcontrib><creatorcontrib>Tapera, Roy</creatorcontrib><creatorcontrib>Mbongwe, Bontle</creatorcontrib><title>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</title><title>BMC research notes</title><addtitle>BMC Res Notes</addtitle><description>Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen. The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X  = 8.98, p &lt; 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients' survival.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Analysis</subject><subject>Antiretroviral therapy</subject><subject>Botswana</subject><subject>Cohort analysis</subject><subject>Combination antiretroviral therapy</subject><subject>Comorbidity</subject><subject>Complications and side effects</subject><subject>Data collection</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes-related comorbidities</subject><subject>Distribution</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV carriers</subject><subject>Human immunodeficiency virus</subject><subject>Incidence</subject><subject>Medical records</subject><subject>Patients</subject><subject>PLHIV</subject><subject>Research Note</subject><subject>Sample size</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Type 2 diabetes</subject><issn>1756-0500</issn><issn>1756-0500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUstu1DAUjRCIlsIHsEGW2MAixY84iVlUKhXQkSp1A91aftxMPUrswXZa-iH8L56ZUjoIeWH7-pxz5XNPVb0m-JiQvv2QCCO4qTHpa0aaphZPqkPS8bbGHOOnj84H1YuUVhi3pO_J8-qACiYIZuKw-rXwxlnwBlAYkHVKQ4aEJhhHl-dURxhVBotMmELUzrrsyrOagl-itSoXn8s1Z_DWlVK-DWhSqxDR-eIKmdF5ZxJyHn0KOd0qrz4ihQit70BFFCHHkNZgsruB0uE6xIxSnu3dy-rZoMYEr-73o-r7l8_fzs7ri8uvi7PTi9pwLEStWSeoMcCoEtoI03DQzBDKtaCixZp2vcFGt0LwBtsOBCsGaAJsaBgRhXdULXa6NqiVXEc3qXgng3JyWwhxKVXMzowgNeWNtcXuftgcjCCqBdGDtbojw1brZKe1nvUE1hRnohr3RPdfvLuWy3AjeSfahvVF4N29QAw_ZkhZTi6ZMgjlIcxJElGmJjijTYG-_Qe6CnP0xSpJO0EYpViwv6ilKh9wfgilr9mIylPetLjjeNv2-D-osixMzgQPgyv1PcL7PULBZPiZl2pOSS4ur_axZIc1ZdIpwvDgB8Fyk2G5y7AsGZabDEtROG8eG_nA-BNa9hsPi-0n</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Rankgoane-Pono, Goabaone</creator><creator>Tshikuka, Jose Gaby</creator><creator>Magafu, Mgaywa Gilbert Mjungu Damas</creator><creator>Masupe, Tiny</creator><creator>Molefi, Mooketsi</creator><creator>Hamda, Shimeles Genna</creator><creator>Setlhare, Vincent</creator><creator>Tapera, Roy</creator><creator>Mbongwe, Bontle</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180201</creationdate><title>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</title><author>Rankgoane-Pono, Goabaone ; Tshikuka, Jose Gaby ; Magafu, Mgaywa Gilbert Mjungu Damas ; Masupe, Tiny ; Molefi, Mooketsi ; Hamda, Shimeles Genna ; Setlhare, Vincent ; Tapera, Roy ; Mbongwe, Bontle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Analysis</topic><topic>Antiretroviral therapy</topic><topic>Botswana</topic><topic>Cohort analysis</topic><topic>Combination antiretroviral therapy</topic><topic>Comorbidity</topic><topic>Complications and side effects</topic><topic>Data collection</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes-related comorbidities</topic><topic>Distribution</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV carriers</topic><topic>Human immunodeficiency virus</topic><topic>Incidence</topic><topic>Medical records</topic><topic>Patients</topic><topic>PLHIV</topic><topic>Research Note</topic><topic>Sample size</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rankgoane-Pono, Goabaone</creatorcontrib><creatorcontrib>Tshikuka, Jose Gaby</creatorcontrib><creatorcontrib>Magafu, Mgaywa Gilbert Mjungu Damas</creatorcontrib><creatorcontrib>Masupe, Tiny</creatorcontrib><creatorcontrib>Molefi, Mooketsi</creatorcontrib><creatorcontrib>Hamda, Shimeles Genna</creatorcontrib><creatorcontrib>Setlhare, Vincent</creatorcontrib><creatorcontrib>Tapera, Roy</creatorcontrib><creatorcontrib>Mbongwe, Bontle</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints Resource Center</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC research notes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rankgoane-Pono, Goabaone</au><au>Tshikuka, Jose Gaby</au><au>Magafu, Mgaywa Gilbert Mjungu Damas</au><au>Masupe, Tiny</au><au>Molefi, Mooketsi</au><au>Hamda, Shimeles Genna</au><au>Setlhare, Vincent</au><au>Tapera, Roy</au><au>Mbongwe, Bontle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study</atitle><jtitle>BMC research notes</jtitle><addtitle>BMC Res Notes</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>11</volume><issue>1</issue><spage>90</spage><epage>90</epage><pages>90-90</pages><artnum>90</artnum><issn>1756-0500</issn><eissn>1756-0500</eissn><abstract>Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen. The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X  = 8.98, p &lt; 0.003). Data from this study showed that the risk of developing DRCs per year of exposure was significantly greater for patients on first-line compared to those who were on second-, third-line regimen; which, suggests that monitoring of cART long-term side effects and regular reviewing of cART regimens is important. Meticulous selection of drug combinations is a key to improving recipients' survival.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>29391039</pmid><doi>10.1186/s13104-018-3144-9</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1756-0500
ispartof BMC research notes, 2018-02, Vol.11 (1), p.90-90, Article 90
issn 1756-0500
1756-0500
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b254dd1048f54ddc91a6e98eddb71fce
source PMC; ProQuest - Publicly Available Content Database
subjects Acquired immune deficiency syndrome
AIDS
Analysis
Antiretroviral therapy
Botswana
Cohort analysis
Combination antiretroviral therapy
Comorbidity
Complications and side effects
Data collection
Development and progression
Diabetes
Diabetes mellitus
Diabetes-related comorbidities
Distribution
Drug therapy
Health aspects
Highly active antiretroviral therapy
HIV
HIV carriers
Human immunodeficiency virus
Incidence
Medical records
Patients
PLHIV
Research Note
Sample size
Survival
Survival analysis
Type 2 diabetes
title Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T06%3A00%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20diabetes%20mellitus-related%20comorbidities%20among%20patients%20attending%20two%20major%20HIV%20clinics%20in%20Botswana:%20a%2012-year%20retrospective%20cohort%20study&rft.jtitle=BMC%20research%20notes&rft.au=Rankgoane-Pono,%20Goabaone&rft.date=2018-02-01&rft.volume=11&rft.issue=1&rft.spage=90&rft.epage=90&rft.pages=90-90&rft.artnum=90&rft.issn=1756-0500&rft.eissn=1756-0500&rft_id=info:doi/10.1186/s13104-018-3144-9&rft_dat=%3Cgale_doaj_%3EA546075038%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5099-b3792cce32a9bc9c45eb3c125b92960b278c0cb699540d7e93618b1e3f4319ce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2791322093&rft_id=info:pmid/29391039&rft_galeid=A546075038&rfr_iscdi=true